GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Price-to-Owner-Earnings

Alliance Pharma (LSE:APH) Price-to-Owner-Earnings : (As of May. 16, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Price-to-Owner-Earnings?

As of today (2024-05-16), Alliance Pharma's share price is £0.352. Alliance Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Alliance Pharma's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Alliance Pharma was 303.13. The lowest was 7.82. And the median was 18.50.


LSE:APH's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.45
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Alliance Pharma's share price is £0.352. Alliance Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.01. Therefore, Alliance Pharma's PE Ratio for today is At Loss.

As of today (2024-05-16), Alliance Pharma's share price is £0.352. Alliance Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was £0.03. Therefore, Alliance Pharma's PE Ratio without NRI for today is 11.73.

During the past 13 years, Alliance Pharma's highest PE Ratio without NRI was 21.22. The lowest was 6.83. And the median was 14.06.


Alliance Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Alliance Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Price-to-Owner-Earnings Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.11 15.29 12.00 19.78 -

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 19.78 - - -

Competitive Comparison of Alliance Pharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Price-to-Owner-Earnings falls into.



Alliance Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Alliance Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.352/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma  (LSE:APH) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Alliance Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q4 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2018 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024